Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 822

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 822
---
 to the other Party.

3.7 Scope of Governance.
Notwithstanding the creation of the JSC, each Party shall retain the rights, powers and discretion granted to it hereunder, and the JSC shall not be delegated or vested with rights, powers or discretion unless such delegation or vesting is expressly
provided herein, or the Parties expressly so agree in writing. The JSC shall not have the power to amend or modify this Agreement, and no decision of the JSC shall be in contravention of any terms and conditions of this Agreement. The Alliance
Managers shall not have any rights, powers or discretion except as expressly granted to the Alliance Managers hereunder and in no event shall the Alliance Managers have any power to modify or amend this Agreement. [***].

3.8 Discontinuation of JSC.The JSC shall continue to exist until Parties mutually agree to disband the JSC. Once the JSC
is disbanded, the JSC shall have no further obligations under this Agreement and, thereafter, the Alliance Managers shall be the points of contact for the exchange of information under this Agreement.

ARTICLE IV

CONTRACT RESEARCH SERVICES

4.1 Overview.During the Term, and subject to the terms and conditions of this Agreement, WuXi Biologics shall, and
if applicable shall cause its Affiliates to, conduct, in consultation with Aadi and under the oversight of the JSC, certain contract research services (the “CRO Services”).

ARTICLE V

MANUFACTURE AND SUPPLY

5.1 Overview. Except as expressly set forth in this ARTICLE V, and as between the Parties, Aadi, directly and/or
through its Affiliates and/or one or more Third Parties, shall control activities with respect to Manufacturing and supplying Licensed Products and the components thereof (including Licensed ADCs) for Development and/or Commercialization by or under
the authority of Aadi in the Territory.

5.2 Supply.

(a) Development Supply. In addition to providing the materials as set forth in Section 2.3(d), WuXi Biologics, directly
and/or through its Affiliates and/or one or more Third Parties, shall [***].

G-13

(b) Clinical and Commercial Supply. Subject to the terms and conditions of this
Agreement, until the date on which Aadi assumes control of activities for manufacturing Licensed ADCs and Licensed Products which shall be in Aadi’s sole discretion, WuXi Biologics shall, directly and/or through its